泮托拉唑钠用于治疗急性心肌梗死伴消化道出血患者的临床疗效及对心血管不良事件的影响

Clinical Effects of Pantoprazole Sodium in the Treatment of Acute Myocardial Infarction with Gastrointestinal Hemorrhage and Its Effects on Cardiovascular Adverse Events

目的探讨泮托拉唑钠用于治疗急性心肌梗死(AMI)伴消化道出血患者的临床疗效及对心血管不良事件的影响。方法选取2018年1月至2019年12月中山市坦洲医院收治的88例AMI伴消化道出血患者作为研究对象,按照治疗方法不同分为观察组(n=45例)和对照组(n=43例)。对照组予以阿司匹林肠溶片联合奥美拉唑钠肠溶片治疗,观察组采用阿司匹林肠溶片联合泮托拉唑钠肠溶片治疗。比较两组治疗后的临床疗效、凝血四项、药物不良反应,随访2个月观察两组心血管不良事件发生情况。结果观察组治疗有效率为88.89%,高于对照组的72.09%,差异有统计学意义(P<0.05);治疗后观察组纤维蛋白原(FIB)水平低于对照组,而凝血酶时间(TT)、活化部分凝血活酶时间(APTT)及凝血酶原时间(PT)水平高于对照组,差异有统计学意义(P<0.05);观察组药物不良反应发生率及心血管不良事件发生率分别为5.11%、6.67%,而对照组分别为6.98%、9.30%,两组不良反应及心血管不良事件发生率比较,差异无统计学意义(P>0.05)。结论泮托拉唑钠用于治疗AMI伴消化道出血可提高治疗效果,且不增加不良反应及心血管不良事件发生。

Objective To explore the clinical effects of pantoprazole sodium in the treatment of acute myocardial infarction(AMI) with gastrointestinal hemorrhage and its effects on cardiovascular adverse events. Methods A total of 88 patients with AMI and gastrointestinal hemorrhage in Tanzhou Hospital of Zhongshan City from January 2017 to December 2019 were selected as the research objects. According to the treatment method, they were divided into a study group(n=45 cases) and a control group(n=43 cases). The control group was treated with aspirin enteric coated tablets(50 mg, qd) + omeprazole sodium(10 mg, bid). The study group was treated with aspirin enteric coated tablets(50 mg, qd) + pantoprazole sodium(20 mg, qd). The clinical effects, four items of coagulation, adverse drug reactions and the occurrence of adverse cardiovascular events after 2 months follow-up were compared. Results The effective rate of the study group was 88.89%, higher than 72.09% of the control group, with statistical significance(P<0.05);the FIB level of the study group was lower than the control group after treatment, while the TT, APTT and PT levels were higher than the control group, with statistical significance(P < 0.05);the incidence of adverse drug reactions and cardiovascular adverse events in the study group were 5.11% and 6.67%, respectively. The control group was 6.98% and 9.30% respectively. There was no statistically significant difference in the incidence of adverse reactions and cardiovascular adverse events between the 2 groups(P>0.05). Conclusion Pantoprazole sodium in the treatment of AMI with gastrointestinal hemorrhage can improve the treatment effects, and does not increase the incidence of adverse reactions and cardiovascular adverse events.